| Company Name: |
3B Pharmachem (Wuhan) International Co.,Ltd.
|
| Tel: |
821-50328103-801 18930552037 |
| Email: |
3bsc@sina.com |
| Products Intro: |
Product Name:13,14-DIHYDROPROSTAGLANDIN E1
CAS:19313-28-1
Purity:99% HPLC Package:1Mg ; 5Mg;10Mg ;100Mg;250Mg ;500Mg ;1g;2.5g ;5g ;10g
|
| Company Name: |
ChemStrong Scientific Co.,Ltd
|
| Tel: |
0755-0755-66853366 13670046396 |
| Email: |
sales@chem-strong.com |
| Products Intro: |
Product Name:13,14-dihydro Prostaglandin E1
CAS:19313-28-1
Purity:95% HPLC Package:10mg;25mg;50mg;100mg
|
| Company Name: |
Shanghai Synchem Pharma Co., ltd
|
| Tel: |
21-619849051-1 18521059765 |
| Email: |
synchempharma@aliyun.com |
| Products Intro: |
Product Name:13,14-DIHYDROPROSTAGLANDIN E1
CAS:19313-28-1
Purity:95%+
|
|
| | 15(R)-PROSTAGLANDIN E1 Basic information |
| Product Name: | 15(R)-PROSTAGLANDIN E1 | | Synonyms: | 9-OXO-11ALPHA,15S-DIHYDROXY-PROSTAN-1-OIC ACID;13,14-DIHYDROPROSTAGLANDIN E1;PGE0;13,14-Dihydroprostaglandinee1;13,14-dihydro PGE1;7-[(1R,2R,3R)-3-hydroxy-2-[(3S)-3-hydroxyoctyl]-5-oxocyclopentyl]heptanoic acid;(11R)-11α,15α-Dihydroxy-9-oxoprostan-1-oic acid;Prostan-1-oic acid,11,15-dihydroxy-9-oxo-, (11a,15S)- | | CAS: | 19313-28-1 | | MF: | C20H36O5 | | MW: | 356.5 | | EINECS: | | | Product Categories: | | | Mol File: | 19313-28-1.mol |  |
| | 15(R)-PROSTAGLANDIN E1 Chemical Properties |
| Boiling point | 541.4±35.0 °C(Predicted) | | density | 1.075±0.06 g/cm3(Predicted) | | storage temp. | Refrigerator, under inert atmosphere | | solubility | Ethyl Acetate, Methanol, Tetrahydrofuran | | form | Colorless to pale yellow oil | | pka | 4.77±0.10(Predicted) | | Stability: | Volatile |
| | 15(R)-PROSTAGLANDIN E1 Usage And Synthesis |
| Description | 13,14-dihydro Prostaglandin E1 (13,14-dihydro PGE1) is a biologically active metabolite of PGE1 with comparable potency to the parent compound. It is an inhibitor of ADP-induced platelet aggregation in human PRP and washed platelets with IC50 values of 31 and 21 nM, respectively. 13,14-dihydro PGE1 is a slightly more potent inhibitor of ADP-induced human platelet aggregation than PGE1 which has an IC50 value of 40 nM. Also, 13,14-dihydro PGE1 was shown to activate adenylate cyclase in NCB-20 hybrid cells with a Kact value of 668 nM. | | Uses | Prostaglandin E0 is a metabolite of Prostaglandin E1 (P838600) and can inhibit aggregation, ATP release, and thromboxane generation by human platelets. Prostaglandin E0 can also decrease the formation of cyclooxygenase (COX) metabolites by inhibiting the induction of COX-2 protein by LPS. | | Definition | ChEBI: 13,14-Dihydro PGE1 is a prostanoid. | | References | [1] [1]? ?NGG?RD E. The Biological Activities of Three Metabolites of Prostaglandin E1[J]. Acta Physiologica, 1966, 66 4: 509-510. DOI: 10.1111/j.1748-1716.1966.tb03231.x
[2] M. HAMBERG B S. On the Metabolism of Prostaglandins E1 and E2 in Man[J]. Journal of Biological Chemistry, 1971, 246 1: 6713-6721. DOI: 10.1016/s0021-9258(19)45905-x
[3] G. KOBZAR. Comparison of the inhibitory effect of E-prostaglandins in human and rabbit platelet-rich plasma and washed platelets[J]. Comparative Biochemistry and Physiology Part C: Pharmacology, Toxicology and Endocrinology, 1993, 106 2: Pages 489-494. DOI: 10.1016/0742-8413(93)90168-k
[4] I. J?RVING. ANTIAGGREGATING POTENCY OF E-TYPE PROSTAGLANDINS IN HUMAN AND RABBIT PLATELETS[J]. Proceedings of the Estonian Academy of Sciences. Chemistry, 1991, 32 1. DOI: 10.3176/chem.1991.3.09
[5] I.A. BLAIR J. M C N HENSBY. PROSTACYCLIN-DEPENDENT ACTIVATION OF ADENYLATE CYCLASE IN A NEURONAL SOMATIC CELL HYBRID: PROSTANOID STRUCTURE-ACTIVITY RELATIONSHIPS[J]. British Journal of Pharmacology, 1980, 69 3: 519-525. DOI: 10.1111/j.1476-5381.1980.tb07043.x |
| | 15(R)-PROSTAGLANDIN E1 Preparation Products And Raw materials |
|